You are here

Final Approval Granted for Generic Equivalent of Amaryl Tablets

PITTSBURGH, Nov. 29 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE:MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Glimepiride Tablets, 1 mg, 2 mg, and 4 mg. Glimepiride Tablets are the AB-rated generic equivalent of Aventis Pharmaceuticals' Amaryl(R) Tablets, which had U.S. sales of approximately $348 million for the 12-month period ending June 30, 2005, according to IMS Health.

Source: Mylan Laboratories, Inc.

Recent Headlines

Company says it is offering a more affordable generic to the agent used to treat varicose veins
Company, FDA held a meeting to discuss trials in bunion, "tummy tuck" patients
New model uses piezoelectric material used in microphones and high-end speakers
Rozanolixizumab touted as possible alternative to standard therapy of corticosteroids, intravenous immunoglobulin
Intrauterine environment may have a 'programming effect' on fetal heart
Heart rate variability may pinpoint who will benefit
Researchers found that ECMO before transplant tripled chance of a long hospital stay